Breast Cancer Drug Won’t Be Offered to 1,000 Patients in England
- NICE’s decision follows end of commercial negotiations
- Pharma companies say watchdog’s methodology is flawed
AstraZeneca’s Enhertu drug.
Source: Business WireThis article is for subscribers only.
England’s drug-price regulator won’t recommend AstraZeneca Plc and Daiichi Sankyo Co.’s breast cancer medicine for about 1,000 extra patients, on the grounds that it isn’t cost effective.
The drug, Enhertu, is already used in the National Health Service to treat patients with high levels of a protein called HER2 in breast tumors. However, the National Institute for Health and Care Excellence said Tuesday that it did not recommend it for advanced HER2-low breast cancer — an advanced, late-stage form of the disease — in England and Wales.